Related Experiment Video
Updated: Aug 18, 2026

The Lambda Select cII Mutation Detection System
Published on: April 26, 2018
Special considerations for conducting genotoxicity tests with protein materials
1Corning Hazleton, Harrogate, UK.
Abstract:
Standard genotoxicity tests are often inappropriate for testing new biological entities, in particular for recombinant proteins which are nature-identical. Arguments that these may contain mutagenic impurities are not substantiated; however, we have produced evidence that such impurities would be detected amidst a vast excess of protein. Concerns that human patients receiving therapy may be at risk from higher-than-physiological levels of proteins are also somewhat theoretical. However, it is apparent that genotoxicity testing will be required for these products for the time being, even if pragmatic approaches reduce the battery of in vitro tests to Ames and chromosomal aberrations only, and reduce the top dose in vivo to 1000x the human therapeutic dose. There is a number of physical and chemical properties of proteins that demand special approaches to methodology if the tests are to produce accurate results. The potential for adsorption to certain forms of glass and plastic means special care must be taken in dissolving and diluting test solutions; adherence to filters means special low protein binding, non-pyrogenic filters should be used for sterilisation of test solutions, where this is necessary; freeze-dried powders aliquotted in multiple vials should be dissolved in minimal solvent and cascaded from vial to vial rather than trying to empty the solid contents for bulk weighing. As proteins are often supplied in solution, in order to achieve sufficiently high test concentrations, it may be necessary to resuspend test bacteria/cells in the test solutions for short periods of time before centrifuging and resuspending in selective or growth media.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Standard genotoxicity tests are unsuitable for novel biological entities like recombinant proteins. Modified testing strategies, including reduced in vitro assays and adjusted in vivo doses, are necessary for these protein-based therapeutics.
Area of Science:
- Biotechnology
- Toxicology
- Pharmaceutical Sciences
Background:
- Standard genotoxicity assays are often ill-suited for evaluating novel biological entities, particularly nature-identical recombinant proteins.
- Concerns regarding mutagenic impurities in recombinant proteins are largely unsubstantiated, as such impurities would likely be detected within the protein excess.
- Theoretical risks associated with higher-than-physiological protein levels in patients undergoing therapy exist but require further investigation.
Purpose of the Study:
- To address the challenges of genotoxicity testing for recombinant proteins.
- To propose pragmatic approaches for genotoxicity testing of protein-based therapeutics.
- To highlight the need for specialized methodologies due to the unique physicochemical properties of proteins.
Main Methods:
- Review of current genotoxicity testing paradigms for biological entities.
- Proposal for a reduced battery of in vitro tests (Ames test, chromosomal aberration assay).
- Recommendation for a reduced top dose in vivo (1000x human therapeutic dose).
Main Results:
- Evidence suggests that mutagenic impurities in recombinant proteins would be detectable.
- Genotoxicity testing for protein-based products will likely remain a requirement.
- Specialized methodological approaches are crucial for accurate protein genotoxicity testing.
Conclusions:
- Modified genotoxicity testing strategies are necessary for recombinant proteins.
- Careful consideration of protein properties like adsorption and solubility is essential for test accuracy.
- Despite theoretical concerns, current evidence supports the safety of recombinant protein therapies with appropriate testing.
Related Concept Videos
Protein Denaturation
Mutagenicity and Carcinogenicity

